ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / GDTC / earnings
GTBP (36) LSTA (29) TVRD (32) ASBP (40) ⌘ Pro Terminal →

CytoMed Therapeutics Limited (GDTC) Next Earnings Date & Expected ±12.5% Move

$0.92 +2.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.92

CytoMed Therapeutics Limited (GDTC) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →
ROARABLE D+ • SELL / AVOID Cap $10.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GDTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GDTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, CytoMed Therapeutics Limited (NASDAQ: GDTC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $0.92 (+2.02% 1D, market cap $10.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GDTC ranks #248 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GDTC compare to GTBP and LSTA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GDTC carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GTBP (GT Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and LSTA (Lisata Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M). Among the 5-stock peer group, GDTC leads on earnings multiple (N/A) while GTBP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GDTC?
▼

For CytoMed Therapeutics Limited (GDTC), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #248 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.92 (+0.17%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510052
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (8)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE GDTC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GDTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY GDTC SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($304.3K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$0.87+0% Next Q
Q2 (-2Q)
47
Grade D$0.87+2.3% Next Q
Q3 (-1Q)
49
Grade D$0.89+3.4% Next Q
Current
52
Grade D+$0.92-1.1% Hist 90D α
Trajectory: D (44) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GDTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GDTC currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.90) and Max Pain ($0.97) forces dealer call-delta covering toward $3.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GDTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GDTC Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 52%NO 48%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.12 Expected Swing
$1.00 (-12.5%)Spot $0.92$1.04 (+12.5%)
MODEL EARNINGS SETUP GAUGE

GDTC Quantitative Pre-Earnings Setup: 52/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (52/100)Model Risk Weight (48/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GDTC)

  • ✓Walkthrough of GDTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GDTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.00%📐 HORIZONTAL RANGE
2026-11-03O $0.90H $0.92L $0.90C $0.92VOL 11.4K
RES: $1.08SUP: $0.68SMA50: $0.90SMA200: $0.98
$1.61$1.36$1.11$0.85$0.60RES $1.08SUP $0.68$0.922026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GDTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GDTC Butterfly Map → + Track GDTC →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GDTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GDTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GDTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GDTC)

Health Care Rank #248 of 1016 ⚔️ GTBP vs GDTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GDTC vs. GTBP, LSTA, TVRD, ASBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CytoMed Therapeutics Limited (GDTC) ranks #248 by composite RQD confidence (52/100, grade D+) and #887 by equity capitalization ($10.9M). Within this direct 5-issuer industry benchmark cohort, GDTC leads on earnings valuation at N/A trailing P/E, while GTBP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GDTC currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GDTC ACTIVE
CytoMed Therapeutics Limited
D+ 52/100 — — — +2.02% $10.9M Benchmark Subject
GTBP
GT Biopharma Inc.
D- 36/100 — — -35.0% -5.00% $11.0M /gtbp-vs-gdtc →
LSTA
Lisata Therapeutics Inc.
E 29/100 — — -35.0% +0.99% $11.0M /lsta-vs-gdtc →
TVRD
Tvardi Therapeutics Inc.
E 32/100 — — -35.0% -8.13% $10.6M /tvrd-vs-gdtc →
ASBP
Aspire-Lakewood Holdings Inc.
D- 40/100 — -1.9% -35.0% -4.36% $11.4M /asbp-vs-gdtc →

2. GDTC Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

CytoMed Therapeutics Limited (GDTC) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $10.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GDTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GDTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, CytoMed Therapeutics Limited (NASDAQ: GDTC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $0.92 (+2.02% 1D, market cap $10.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GDTC ranks #248 in composite RQD confidence.

How does GDTC compare to GTBP and LSTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GDTC carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GTBP (GT Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and LSTA (Lisata Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M). Among the 5-stock peer group, GDTC leads on earnings multiple (N/A) while GTBP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GDTC?

For CytoMed Therapeutics Limited (GDTC), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #248 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GDTC trading relative to its 50-day, 200-day, and 52-week technical levels?

GDTC last traded at $0.92 (+2.02% on volume of 11,444 shares), positioning the stock +2.22% above its 50-day simple moving average ($0.90) and -6.12% below its 200-day simple moving average ($0.98). Across its 52-week range of $0.68 to $3.10, GDTC sits at the 9.9% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.04).

GDTC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is GDTC's next earnings date?

Based on SEC filing cadence, CytoMed Therapeutics Limited (GDTC)'s next quarterly reporting window is estimated around Upcoming Quarter.

How much is GDTC stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for GDTC, spanning a range between $1 and $1.04.

Direct Sub-Reports: GDTC RQD Cockpit GDTC 12M Forecast GDTC Earnings & Move GDTC Dividends & DRIP GDTC Insiders & 13F GDTC Whale Options GDTC Profit Sankey GDTC News & Why
ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GDTC — CytoMed Therapeutics Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:20:08Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GDTC scores 52 out of 100, a D+ grade labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 8/20 (institutional accumulation and options positioning), Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillars are the cash engine and institutional/insider flow, where the score reflects zero reported return on invested capital, zero free-cash-flow yield, and modest positioning signals. The forensic balance sheet is the strongest pillar, indicating the company's financial-distress and accounting-quality measures sit in a more favorable range than its earnings-based measures. For a prospective investor, the upside case depends on balance-sheet resilience and any future improvement in cash generation, while the valuation tradeoff is that the stock currently generates no reported profit or free cash flow against a $10.7M market capitalization. Per the Roarable RQD rating, the overall verdict is a sell-side posture of trimming exposure rather than accumulating.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, the most frequent item is a Nasdaq notification regarding a minimum bid price deficiency, reported by Moomoo and GlobeNewswire, which is flagged as a yellow market-wire item. A separate report from Stock Titan states that an insider entity sold 145,400 shares, updating its ownership. A Yahoo! Finance Canada seasonal-returns item and a Yahoo! Finance Canada item referencing XORTX Therapeutics are classified as yellow market-wire items. The most recent item is a green catalyst reporting that the stock ticked up 1.15% to $0.88 as shares pressed against near-term resistance, with an option-strike build referenced. Risk watch items are the bid-price deficiency notice and the insider share sale. The feed lists no proprietary signals. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What are the reported revenue, operating income, net income, and cash-flow figures underlying the 0% margins and ROIC?
  • What is the company's cash balance and debt schedule behind the Debt/Equity of 0.5?
  • What is the timeline and remediation plan for the Nasdaq minimum bid price deficiency?
  • Who are the reporting insiders behind the 145,400-share sale, and what is their holding after the sale?
  • Is there any analyst coverage or institutional ownership data to corroborate the flow-related pillar scores?

GDTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CytoMed Therapeutics Limited (GDTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GDTC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GDTC Bull vs. Bear Conversation Board — What's Your Call at $0.92?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GDTC 🐻 50% BEARISH CONVICTION
1. Pick Your Side on GDTC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $0.97 (+7.8%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GDTC (D+ • RQD 52/100) a Buy at $0.90?

Welcome to the GDTC (CytoMed Therapeutics Limited) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.72 (-20.0%)
Spot @ $0.90

Pump the brakes on GDTC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GDTC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless CytoMed Therapeutics Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.15 (+27.8%)
Spot @ $0.90

GDTC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GDTC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.90 (52-wk range $0.68 - $3.10), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%